Key facts
- Notable investors include HaiBang Ventures, Yantai Tongju Private Equity (Investment) Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for T-Maximum
- ·The full record, as it builds
Funding rounds
No funding rounds for T-Maximum are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About T-Maximum
Developer of CAR-T Cell therapies intended to treat brain tumors. The company has a unique universal CAR-T development platform, CRISPR/Cas9 Gene-Editing platform, which effectively solves the two major pain points, GvHD and HvG, in this field. The allogeneic CAR-T cells developed by the company can survive in patients for a long time and have achieved promising therapeutic effects, enabling doctors and patients to access CAR-T therapies for brain tumors
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2017
- Employees
- 48
- Website
- t-maximum.com/
- Ownership
- Privately Held (backing)
T-Maximum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in T-Maximum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on T-Maximum in its N-PORT filings yet. We sweep new filings monthly.